A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (NCT07216703)
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment
Who can join: Review the eligibility criteria below.
Location: Florida Cancer Specialists - South ( Site 7001) — Fort Myers, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (166 Sites)
Showing the first 25 of 166 sites.
- Florida Cancer Specialists - South ( Site 7001) — Fort Myers, Florida
- Mount Sinai Braman Comprehensive Cancer Center ( Site 5043) — Miami Beach, Florida
- Mount Sinai Comprehensive Cancer Center ( Site 6000) — Miami Beach, Florida
- Florida Cancer Specialists - East ( Site 7000) — West Palm Beach, Florida
- Winship Cancer Institute of Emory University ( Site 5005) — Atlanta, Georgia
- Nancy N. & J.C. Lewis Cancer and Research Pavillion - Research Department ( Site 6005) — Savannah, Georgia
- TRIALS 365 ( Site 6008) — Shreveport, Louisiana
- Maryland Oncology Hematology (MOH) ( Site 8001) — Columbia, Maryland
- Minnesota Oncology Hematology, PA ( Site 8003) — Edina, Minnesota
- Women's Cancer Center of Nevada ( Site 6011) — Las Vegas, Nevada
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009) — New York, New York
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6001) — Tulsa, Oklahoma
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007) — Eugene, Oregon
- Asplundh Cancer Pavilion ( Site 5002) — Willow Grove, Pennsylvania
- Women & Infants Hospital ( Site 6003) — Providence, Rhode Island
- University of Tennessee Medical Center ( Site 6012) — Knoxville, Tennessee
- Texas Oncology - DFW ( Site 8005) — Fort Worth, Texas
- Houston Methodist Hospital-Obstetrics and Gynecology ( Site 6010) — Houston, Texas
- Texas Oncology-The Woodlands ( Site 8000) — The Woodlands, Texas
- Texas Oncology - Northeast Texas ( Site 8002) — Tyler, Texas
- University of Virginia Cancer Center ( Site 5044) — Charlottesville, Virginia
- University of Virginia Cancer Center ( Site 6014) — Charlottesville, Virginia
- Inova Schar Cancer Institute ( Site 5045) — Fairfax, Virginia
- Centro de Oncología e Investigación de Buenos Aires ( Site 0107) — Berazategui, Buenos Aires
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 0105) — Mar del Plata, Buenos Aires
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cervical Cancer
- SUCCESS - Feasibility of HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions (HPV Study) — Ouagadougou,
- Dostarlimab and Cobolimab in Advanced Cervical Cancer — Boston, Massachusetts
- International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer — Liège,
- Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement — Houston, Texas
- Sexual Health Empowerment for Women's Health — Kansas City, Missouri
- Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique — Houston, Texas
Explore by condition: All Cervical Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.